- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06120673
REmission in Membranous Nephropathy International Trial (REMIT) (REMIT)
International, Multi-centre Randomised Clinical Trial of Obinutuzumab Versus Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy (REMIT Trial).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Peta-Anne Paul-Brent
- Phone Number: +61411 397 776
- Email: remit@uq.edu.au
Study Locations
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia
- Canberra Hospital
-
Contact:
- Giles Walters, Dr
-
-
New South Wales
-
Camperdown, New South Wales, Australia
- Royal Prince Alfred Hospital
-
Contact:
- Steve Chadban, Prof
-
-
Queensland
-
Birtinya, Queensland, Australia
- Sunshine Coast University Hospital
-
Contact:
- Nicholas Gray, Dr
-
Brisbane, Queensland, Australia
- Royal Brisbane and Women'S Hospital
-
Contact:
- Sharad Ratanjee, Dr
-
Bundaberg, Queensland, Australia
- Bundaberg Hospital
-
Contact:
- Clyson Mutatiri, Dr
-
Cairns, Queensland, Australia
- Cairns Hospital
-
Contact:
- Harris Abdul Makim, Dr
-
Logan, Queensland, Australia
- Logan Hospital
-
Contact:
- Jeremy Frazier, Dr
-
Mackay, Queensland, Australia
- Mackay Base Hospital
-
Contact:
- Roy Cherian, Dr
-
Rockhampton, Queensland, Australia
- Rockhampton Hospital
-
Contact:
- Than Han, Dr
-
South Brisbane, Queensland, Australia
- Mater Hospital
-
Contact:
- Michael Burke, Dr
-
Woolloongabba, Queensland, Australia
- Princess Alexandra Hospital
-
Contact:
- Ross Francis, A/Prof
-
-
Tasmania
-
Hobart, Tasmania, Australia
- Royal Hobart Hospital
-
Contact:
- Steven Y"ew, Dr
-
-
Western Australia
-
Murdoch, Western Australia, Australia
- Fiona Stanley Hospital
-
Contact:
- Ramyasuda Swaninatha, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Able to provide informed consent.
Primary Membranous Nephropathy (PMN) confirmed by:
- Kidney biopsy (anti-PLA2R negative patients are eligible for inclusion if PMN is confirmed on biopsy. Kidney biopsy is generally encouraged to confirm diagnosis of PMN) or
- if the clinician decides against a biopsy, the patient must be anti-PLA2R positive and must not have diabetes.
- Proteinuria ≥4 g/24h despite supportive treatment for at least 6 months with maximally tolerated dose of ACE-i or ARB (dose to be stable for at least 4 weeks), confirmed at final screening before randomisation
- Serum albumin <30 g/L.
- Estimated glomerular filtration rate (eGFR) ≥40 ml/min/1.73m2.
- Treatment with immunosuppression is warranted, as determined by the treating physician.
- Fully vaccinated against COVID-19 according to local practice/recommendation.
Exclusion Criteria:
- Resistant to rituximab or have had >2 g of rituximab in the past.
- Resistant to cyclophosphamide or have had a cumulative >20 g of cyclophosphamide in the past.
- More than 3 years since PMN diagnosis.
- Proteinuria must not have decreased by >50% over 6 months whilst taking ACE-i/ARB.
- Patients with human immunodeficiency virus (HIV) infection, active hepatitis B or C infection, or other active infections.
- Patients with secondary membranous nephropathy
- Screening for malignancy must be considered especially in cases who are anti-PLA2R negative.
- Patients whose kidney biopsy shows concomitant features of diabetic nephropathy.
- Kidney transplant recipients.
- Pregnancy or breastfeeding.
- Women of childbearing age not willing to use contraception.
- Suspected or known hypersensitivity, allergy, and/or immunogenic reaction history to monoclonal antibodies, corticosteroid, cyclophosphamide, any of their ingredients, and any other drugs from these same pharmacotherapeutic groups.
- Any disorder or condition, in the opinion of the investigator, might pose an unacceptable risk to participant's safety and well-being.
- Inability to understand or comply with the requirements of the study.
- Incapable of recognizing the nature, significance, and scope of the clinical trial or giving consent are excluded, even if they have a legal representative.
- Use of an investigational agent <30 days or within five half-lives of the investigational agents (whichever is longer), whose effect or toxicity may overlap with that of obinutuzumab, prednisolone, cyclophosphamide, or their metabolites.
- Active Tuberculosis infection. Testing for latent disease may be performed at screening if required by local regulations or in accordance with local clinical practice. Latent disease after completion of appropriate treatment is not exclusionary.
- Low peripheral B-cell count (as per local reference range) . B-cell count must be checked, particularly in those who have received rituximab, cyclophosphamide or both anytime in the past.
- Use of SGLT2-i and GLP-1 agonist within 90 days prior to randomisation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Obinutuzumab
|
Participants will receive an intravenous infusion of 1,000mg Obinutuzumab at Weeks 0, 2, 24 and 26. Prior to the administration of obinutuzumab, the participant will receive pre-medications consisting of all three:
|
Active Comparator: Oral prednisolone and cyclophosphamide
|
Participants will receive a combination of oral prednisolone and cyclophosphamide with 2 options (Option A and B). Option A: Cyclical prednisolone and cyclophosphamide with IV methylprednisolone
Option B: Concurrent prednisolone and cyclophosphamide without IV methylprednisolone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A ranked composite measure based efficacy, safety and quality of life at 24 months
Time Frame: 24 months
|
A ranked composite measure comprising of:
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants in Complete Remission (CR)
Time Frame: At 6, 12, 18, 24 month
|
Number of participants who have proteinuria of ≤3.0 g/day
|
At 6, 12, 18, 24 month
|
Number of participants in Partial Remission (PR)
Time Frame: At 6, 12, 18, 24 month
|
Number of participants who have proteinuria of between >3.0 and 3.5 g/day and >50% reduction from baseline proteinuria
|
At 6, 12, 18, 24 month
|
Number of participants in CR and/or PR
Time Frame: At 6, 12, 18, 24 month
|
Number of participants who meet complete and/or partial PMN remission definition
|
At 6, 12, 18, 24 month
|
Number of non-serious adverse events of special interest
Time Frame: Up until 24 months
|
Number of protocol defined non-serious events of special interest (related to PMN or the study interventions)
|
Up until 24 months
|
Number of serious adverse events
Time Frame: Up until 24 months
|
Number of protocol defined serious adverse events
|
Up until 24 months
|
Number of participants with a lack of response to PMN treatment
Time Frame: Up until 24 months
|
Number of participants who have <50% reduction in proteinuria from baseline or worsening (increasing in value from baseline) proteinuria, and had not achieved either PR or CR
|
Up until 24 months
|
Number of participants who relapse after CR or PR
Time Frame: Up until 24 months
|
Number of participant who have a reappearance of proteinuria to >3.5 g/day at a ≥50% higher level than the lowest post-treatment value in participants who had previously achieved either PR or CR
|
Up until 24 months
|
Time to first relapse
Time Frame: Up until 24 months
|
The time to relapse is the time interval from the last point in time when the participant was in the best remission status (either PR or CR) to the first relapse
|
Up until 24 months
|
Number of participants who have immunological remission (for anti-PLA2R positive participants)
Time Frame: Up until 24 months
|
Number of participants who have their anti-PLA2R-Ab level drop below 2 RU/mL who are ≥14 RU/ml at baseline
|
Up until 24 months
|
Number of participants who have a requirement for rescue therapy
Time Frame: Up until 24 months
|
Number of participants who have a lack of response or relapse at 12 months, and rescue therapies such as obinutuzumab, calcineurin inhibitors, or additional corticosteroid and cyclophosphamide are used.
|
Up until 24 months
|
Number of participants who exit the trial
Time Frame: Up until 24 months
|
Number participant who cease trial follow-up for any reason
|
Up until 24 months
|
Quality of life scores (EQ-5D-5L)
Time Frame: at 3, 6, 9, 12, 15, 18, 24 months
|
Quality of life scores using EQ-5D-5L
|
at 3, 6, 9, 12, 15, 18, 24 months
|
eGRF slope
Time Frame: Up until 24 months
|
Change in eGFR slope
|
Up until 24 months
|
Number of treatment or PMN associated deaths
Time Frame: Up until 24 months
|
Number of deaths attributed directly or indirectly to a complication of PMN or the treatment for PMN
|
Up until 24 months
|
All cause deaths
Time Frame: Up until 24 months
|
Number of deaths of any cause
|
Up until 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants in Complete Remission (CR)
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who have proteinuria of ≤3.0 g/day
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants in Partial Remission (PR)
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who have proteinuria of between >3.0 and 3.5 g/day and >50% reduction from baseline proteinuria with stable kidney function (eGFR remains >40 ml/min/1.73m2)
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants in CR and/or PR
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who meet complete and/or partial PMN remission definition
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of non-serious adverse events of special interest
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of protocol defined non-serious events of special interest (related to PMN or the study interventions)
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of serious adverse events
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of protocol defined serious adverse events
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants with a lack of response to PMN treatment
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who have <50% reduction in proteinuria from baseline or worsening (increasing in value from baseline) proteinuria, and had not achieved either PR or CR
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who have immunological remission (for anti-PLA2R positive participants)
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who have their anti-PLA2R-Ab level drop below 2 RU/mL who are ≥14 RU/ml at baseline
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Requirement for dialysis or kidney transplant
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants who require dialysis or a kidney transplant (Stage 5 kidney disease)
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
eGRF slope
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Change in eGFR slope
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants with treatment or PMN associated death
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of deaths attributed directly or indirectly to a complication of PMN or the treatment for PMN
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of participants with all cause death
Time Frame: At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Number of deaths of any cause
|
At any point up until end of study (when last participant reaches 24 months - ~42 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Chen Au Peh, The University of Adelaide
- Study Director: Bhadran Bose, Nepean Blue Mountains Local Health District
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Nephritis
- Glomerulonephritis
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Glomerulonephritis, Membranous
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Prednisolone
- Cyclophosphamide
- Obinutuzumab
Other Study ID Numbers
- AKTN 18.03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Data sets will be made available to researchers within the REMIT Study for analysis of sub-studies and country specific outcomes after the primary manuscript has been accepted for publication.
For researchers outside the REMIT study, individual participant data will be made available upon request to a Data Access Committee, a review board set up to assess proposals based on sound science, benefit-risk balancing and research team expertise.
Where data linkage has been used to estimate health care services utilisation, data sharing will be determined by the specific requirements of the data custodians. In some circumstances it may not be possible to share participant level data beyond the country in which it was collected. This will be addressed on a jurisdiction basis.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Data sets will be made available to researchers within the REMIT Study for analysis of sub-studies and country specific outcomes after the primary manuscript has been accepted for publication.
For researchers outside the REMIT study, individual participant data will be made available upon request to a Data Access Committee, a review board set up to assess proposals based on sound science, benefit-risk balancing and research team expertise.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Membranous Nephropathy
-
Shanghai Jiaolian Drug Research and Development...Shanghai Pharmaceuticals Holding Co., LtdRecruiting
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingPrimary Membranous NephropathyChina
-
Beijing Mabworks Biotech Co., Ltd.Recruiting
-
BeiGeneRecruitingPrimary Membranous NephropathyChina, United Kingdom, United States
-
Cerium Pharmaceuticals, Inc.RecruitingPrimary Membranous NephropathyUnited States, India, Canada
-
Beijing Mabworks Biotech Co., Ltd.Recruiting
-
Hoffmann-La RocheActive, not recruitingPrimary Membranous NephropathyUnited States, China, Spain, Argentina, Brazil, France, Italy, Russian Federation, Israel, Poland, Turkey, Ukraine
-
Reistone Biopharma Company LimitedActive, not recruitingPrimary Membranous NephropathyChina
-
Everest Medicines (China) Co.,Ltd.RecruitingPrimary Membranous NephropathyChina
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... and other collaboratorsCompletedMEMBRANOUS NEPHROPATHYSpain
Clinical Trials on Obinutuzumab
-
Institute of Hematology & Blood Diseases Hospital...RecruitingImmune Thrombocytopenia | TreatmentChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Michael ChoiPharmacyclics LLC.Withdrawn
-
Institute of Hematology & Blood Diseases HospitalRecruitingImmune Thrombocytopenia | TreatmentChina
-
Hoffmann-La RocheCompletedFollicular Lymphoma | Chronic Lymphocytic LeukemiaKorea, Republic of
-
French Innovative Leukemia OrganisationHoffmann-La RocheRecruiting
-
The First Affiliated Hospital with Nanjing Medical...RecruitingObinutuzumab | Rapid Infusion | Intravenous Infusion ReactionChina
-
Fondazione Italiana Linfomi - ETSRoche Pharma AGRecruiting
-
Paolo GhiaRecruitingChronic Lymphocytic LeukemiaItaly
-
Polish Myeloma ConsortiumRoche Pharma AG; Bioscience, S.A.UnknownWaldenstrom MacroglobulinemiaPoland